SOURCE: EyeGate Pharma

February 06, 2007 08:01 ET

EyeGate Pharma to Present at the 9th Annual BIO CEO & Investor Conference

WALTHAM, MA -- (MARKET WIRE) -- February 6, 2007 -- EyeGate Pharma, a privately-held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that Stephen From, President and Chief Executive Officer, will present at the 9th Annual BIO CEO & Investor Conference which will be held at The Waldorf-Astoria Hotel in New York City from February 12-14, 2007. Mr. From will present a corporate overview on February 14th at 11:15 AM in the Conrad Suite and he will be available for one-on-one meetings during the conference. For more information about the 9th Annual BIO CEO & Investor Conference please visit

About EyeGate Pharma

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies using the EyeGate® II Delivery System are planned for the fourth quarter of 2007.

Contact Information

  • IR/PR Contact:
    Dory Valiquette
    LaVoie Group
    (978) 745-4200 X106
    Email Contact